Homax Advisory is a thought-leader and Independent Health Economic and Market Access consultancy for pharma and biotech. Vaud canton-based, serving clients across Europe.
Products, services, technology
Services: HEOR and Market Access strategy, health economic modeling, evidence synthesis, HTA preparation, publication planning. Technology: AI-assisted analysis, custom Python modeling, interactive decision models. Expertise: diabetes, metabolic, cardiovascular, devices, rare diseases.
Cooperation possibilities
Seeking collaboration with biotech companies needing Health Economic and Market Access support: early economic modeling, value story development, evidence gap analysis, dossier preparation, publication strategy. Flexible engagement from ad-hoc advisory to full project support. Open to codevelopment.
- +41 79 564 98 79
- Send an email
- Stephane Roze
Some insights
Healthcare systems face tough choices. Our work ensures these decisions are informed by solid economic evidence—not guesswork. When we help a biotech demonstrate real value, patients gain access to treatments that improve their lives. That's the impact behind every model we build.
We built models that shaped reimbursement decisions worldwide. We published research that others cite. Now, as an independent consultancy, we bring that same rigor directly to biotech partners—no layers, no juniors, just decades of hands-on HEOR expertise applied to your challenges.
Lean by design: senior-level expertise on every project, no layers. Decades of modeling and HTA experience. Mycelium Health Alliance network for regulatory, RWE, and specialized needs. Actively developing AI-augmented workflows and seeking collaborations in digital health and advanced analytics.
"He does maths about medicines." Fair enough. More precisely: I build models that calculate whether a new drug or device is good value for healthcare systems. If the numbers work, patients get access. If not, back to the drawing board. High stakes spreadsheets, basically.
Connecting with biotech founders and CMOs in need of Health Economics and Market Access support. Opportunities to share expertise at SBA events. Introductions to companies preparing first HTA submissions, seeking all levels of investors... we can help them get it right the first time.
Biotech leadership teams (CEO, CMO, CFO) facing first reimbursement decisions. HEOR and market access directors. Business development leads exploring European expansion. Healthcare investors needing economic validation. Fellow independents in regulatory, RWE, medical communications for partnerships.
